|[May 19, 2017]
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Neurotrope, Inc. - NTRP
Rosen Law Firm, a global investor rights law firm, announces the filing
of a class action lawsuit on behalf of purchasers of Neurotrope, Inc.
securities (NASDAQ:NTRP) from January 7, 2016 through April 28, 2017,
both dates inclusive (the "Class Period"). The lawsuit seeks to recover
damages for Neurotrope investors under the federal securities laws.
To join the Neurotrope class action, go to http://www.rosenlegal.com/cases-1133.html
or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653
or email email@example.com or firstname.lastname@example.org
for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS
CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU
MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU
MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants throughout the Class Period made
false and/or misleading statements and/or failed to disclose material
adverse information regarding the efficacy of its lead product
candidate, Bryostatin-1.On May 1, 2017, Neurotrope announced "positive
top-line results" of the focal Phase 2b trials of Bryostatin-1,
mentioning "improvement in patients with moderate to severe Alzheimer's
disease," The trial data allegedly negates these statements as the
top-line data relating to the 20 microgram dose of Bryostatin-1 did not
produce statistically significant results. Neurotrope also allegedly
failed to disclose statements about the efficacy of the 40 microgram
dose in connection with its primary and secondary endpoints. On this
news, shares of Neurotrope fell from $18.81 per share on April 28, 2017
to a close at $6.97 per share on May 1, 2017, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as
lead plaintiff, you must move the Court no later than July 17, 2017. If
you wish to join the litigation, go to http://www.rosenlegal.com/cases-1133.html
or to discuss your rights or interests regarding this class action,
please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at
866-767-3653 or via email at email@example.com
Follow us for updates on LinkedIn (News - Alert): https://www.linkedin.com/company/the-rosen-law-firm
or on Twitter (News - Alert): https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation
by Institutional Shareholder Services for the number of securities class
action settlements annually obtained for investors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170519005781/en/
[ Back To HTML5's Homepage ]